Biodesix, Inc. specializes in diagnostic solutions for lung disease, offering blood-based tests such as the Nodify Lung nodule risk assessment and IQLung strategy that combine proteomic and genomic information to evaluate malignancy risk in lung nodules and inform treatment selection for lung cancer patients. These tests support clinical decision-making to expedite personalized care. The company also provides development services to biopharmaceutical partners, encompassing biomarker discovery, assay development, clinical trial sample testing, and commercialization support.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 20 | — | -11.5 | — |
| Q3 2025 | 21.8 | — | -8.7 | — |
| Q4 2025 | 28.8 | — | -4 | — |
| Q1 2026 | 25.6 | — | -7.8 | — |
| Q2 2026 | 26.9 | 34.2% | -7.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: The E.W. Scripps Company (SSP), OraSure Technologies, Inc. (OSUR), Palladyne AI Corp. (PDYN), HireQuest, Inc. (HQI), Eagle Financial Services, Inc. (EFSI), Globa Terra Acquisition Corporation (GTERA)